Inclusion Criteria:

- Patients who have undergone a radical prostatectomy (should have unmeasurable PSA) or
radiation therapy for prostate cancer and who have high risk disease as defined by
one of the following:

- Node positive disease post-operatively

- Capsule involvement

- Seminal Vesicles involvement

- Gleason score ≥ 8

- >50% of core biopsies that are positive

- Clinical Stage T2c and T3

- Pre-op PSA > 15 plus Gleason score of 7

- Age greater than 18

- ECOG Performance Status 0-1

- Serum creatinine <= 1.5 mg/dl

- Granulocyte count >= 1500/m3, Hemoglobin > 8.0 g/dl, and platelet count >=
100,000/m3

- Total bilirubin <= ULN

- AST, ALT and Alkaline Phosphatase must be within the range allowing for
eligibility.

- Signed patient informed consent.

- Men of childbearing potential must be willing to consent to using effective
contraception while on treatment and for three months thereafter.

Exclusion Criteria:

- Peripheral neuropathy > grade 1

- History of severe hypersensitivity to Taxotere® or other drugs formulated with
polysorbate 80.

- Patients who have received previous chemotherapy or are being treated on another
clinical trial using an investigational agent.

- Active infection within 14 days of beginning treatment

- Patients with a serious illness or medical condition, history of significant
neurologic or psychiatric or active infection.

- Patients with a current malignancy. Patients with prior a history of in situ lobular
carcinoma of the breast, basal or squamous cell skin cancer, are eligible.